Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1

Status

Completed 16Active not recruiting 15Recruiting 6Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Papillary renal cell carcinoma, sporadic 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Basal Cell 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Specimen Handling 478pembrolizumab 454Magnetic Resonance Spectroscopy 418Carboplatin 326Cyclophosphamide 312Cisplatin 271Biopsy 270Radiotherapy 243Paclitaxel 228Gemcitabine 227Bevacizumab 211Nivolumab 188fludarabine 183venetoclax 174Drug Therapy 170Dexamethasone 157Blood Specimen Collection 156Oxaliplatin 155Injections 152Capecitabine 151Fluorouracil 144Docetaxel 142Standard of Care 135Radiosurgery 135Rituximab 125Pemetrexed 117durvalumab 114Leucovorin 108Radiation 106atezolizumab 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Erlotinib Hydrochloride × 1 year × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06483555 2026-04-23

PANGEA

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
104 enrolled
DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT03297606 2026-03-27

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting
720 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05442060 2025-08-03

EGFR

OBI Pharma, Inc

Phase 2 Recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡